Psychiatric disorders among hospitalized patients deceased with COVID-19 in Italy.
COVID-19
Death
Hospital
Psychiatric disorders
SARS-CoV-2
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
23
02
2021
revised:
30
03
2021
accepted:
31
03
2021
pubmed:
29
4
2021
medline:
29
4
2021
entrez:
28
4
2021
Statut:
ppublish
Résumé
there is concern about the increased risk for SARS-CoV-2 infection, COVID-19 severe outcomes and disparity of care among patients with a psychiatric disorder (PD). Based on the Italian COVID-19 death surveillance, which collects data from all the hospitals throughout the country, we aimed to describe clinical features and care pathway of patients dying with COVID-19 and a preceding diagnosis of a PD. in this cross-sectional study, the characteristics of a representative sample of patients, who have died with COVID-19 in Italian hospitals between February 21st and August 3rd 2020, were drawn from medical charts, described and analysed by multinomial logistic regression according to the recorded psychiatric diagnosis: no PD, severe PD (SPD) (i.e. schizophrenia and other psychotic disorders, bipolar and related disorders), common mental disorder (CMD) (i.e. depression without psychotic features, anxiety disorders). the 4020 COVID-19 deaths included in the study took place in 365 hospitals across Italy. Out of the 4020 deceased patients, 84 (2•1%) had a previous SPD, 177 (4.4%) a CMD. The mean age at death was 78.0 (95%CI 77.6-78.3) years among patients without a PD, 71.8 (95%CI 69.3-72.0) among those with an SPD, 79.5 (95%CI 78.0-81.1) in individuals with a CMD. 2253 (61.2%) patients without a PD, 62 (73.8%) with an SPD, and 136 (78.2%) with a CMD were diagnosed with three or more non-psychiatric comorbidities.When we adjusted for clinically relevant variables, including hospital of death, we found that SPD patients died at a younger age than those without a PD (adjusted OR per 1 year increment 0.96; 95% CI 0.94-0.98). Women were significantly more represented among CMD patients compared to patients without previous psychiatric history (aOR 1.56; 95% CI 1.05-2.32). Hospital admission from long-term care facilities (LTCFs) was strongly associated with having an SPD (aOR 9.02; 95% CI 4.99-16.3) or a CMD (aOR 2.09; 95% CI 1.19-3.66). Comorbidity burden, fever, admission to intensive care and time from symptoms' onset to nasopharyngeal swab did not result significantly associated with an SPD or with a CMD in comparison to those without any PD. even where equal treatment is in place, the vulnerability of patients with a PD may reduce their chance of recovering from COVID-19. The promotion of personalised therapeutic projects aimed at including people with PD in the community rather than in non-psychiatric LTCFs should be prioritised.
Sections du résumé
BACKGROUND
BACKGROUND
there is concern about the increased risk for SARS-CoV-2 infection, COVID-19 severe outcomes and disparity of care among patients with a psychiatric disorder (PD). Based on the Italian COVID-19 death surveillance, which collects data from all the hospitals throughout the country, we aimed to describe clinical features and care pathway of patients dying with COVID-19 and a preceding diagnosis of a PD.
METHODS
METHODS
in this cross-sectional study, the characteristics of a representative sample of patients, who have died with COVID-19 in Italian hospitals between February 21st and August 3rd 2020, were drawn from medical charts, described and analysed by multinomial logistic regression according to the recorded psychiatric diagnosis: no PD, severe PD (SPD) (i.e. schizophrenia and other psychotic disorders, bipolar and related disorders), common mental disorder (CMD) (i.e. depression without psychotic features, anxiety disorders).
FINDINGS
RESULTS
the 4020 COVID-19 deaths included in the study took place in 365 hospitals across Italy. Out of the 4020 deceased patients, 84 (2•1%) had a previous SPD, 177 (4.4%) a CMD. The mean age at death was 78.0 (95%CI 77.6-78.3) years among patients without a PD, 71.8 (95%CI 69.3-72.0) among those with an SPD, 79.5 (95%CI 78.0-81.1) in individuals with a CMD. 2253 (61.2%) patients without a PD, 62 (73.8%) with an SPD, and 136 (78.2%) with a CMD were diagnosed with three or more non-psychiatric comorbidities.When we adjusted for clinically relevant variables, including hospital of death, we found that SPD patients died at a younger age than those without a PD (adjusted OR per 1 year increment 0.96; 95% CI 0.94-0.98). Women were significantly more represented among CMD patients compared to patients without previous psychiatric history (aOR 1.56; 95% CI 1.05-2.32). Hospital admission from long-term care facilities (LTCFs) was strongly associated with having an SPD (aOR 9.02; 95% CI 4.99-16.3) or a CMD (aOR 2.09; 95% CI 1.19-3.66). Comorbidity burden, fever, admission to intensive care and time from symptoms' onset to nasopharyngeal swab did not result significantly associated with an SPD or with a CMD in comparison to those without any PD.
INTERPRETATION
CONCLUSIONS
even where equal treatment is in place, the vulnerability of patients with a PD may reduce their chance of recovering from COVID-19. The promotion of personalised therapeutic projects aimed at including people with PD in the community rather than in non-psychiatric LTCFs should be prioritised.
Identifiants
pubmed: 33907730
doi: 10.1016/j.eclinm.2021.100854
pii: S2589-5370(21)00134-6
pmc: PMC8062162
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100854Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
Authors have no competing interest to disclose for the present study.
Références
Front Neuroendocrinol. 2014 Aug;35(3):320-30
pubmed: 24887405
Am J Geriatr Psychiatry. 2010 Jun;18(6):475-82
pubmed: 21217558
Lancet Public Health. 2020 Aug;5(8):e444-e451
pubmed: 32619408
Aging Ment Health. 2019 Mar;23(3):287-296
pubmed: 29266972
Front Psychiatry. 2020 Sep 30;11:578465
pubmed: 33132938
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):600-14
pubmed: 27042910
Lancet Psychiatry. 2020 May;7(5):387-388
pubmed: 32353267
Front Public Health. 2020 May 08;8:167
pubmed: 32573563
BMC Psychiatry. 2020 Feb 17;20(1):70
pubmed: 32066421
Lancet Psychiatry. 2020 Apr;7(4):e21
pubmed: 32199510
Lancet Psychiatry. 2020 Dec;7(12):1054-1063
pubmed: 33031760
World Psychiatry. 2017 Jun;16(2):163-180
pubmed: 28498599
J Clin Psychiatry. 2020 Apr 28;81(3):
pubmed: 32369691
Euro Surveill. 2020 Jun;25(22):
pubmed: 32524949
Lancet Psychiatry. 2021 May;8(5):356-359
pubmed: 33609450
Soc Psychiatry Psychiatr Epidemiol. 2006 Nov;41(11):853-61
pubmed: 16915360
BMC Psychiatry. 2016 Jul 26;16:263
pubmed: 27455845
Lancet Psychiatry. 2021 Feb;8(2):130-140
pubmed: 33181098
JAMA Psychiatry. 2020 Sep 1;77(9):974-976
pubmed: 32352480
World Psychiatry. 2021 Feb;20(1):124-130
pubmed: 33026219
Schizophr Res. 2018 Sep;199:154-162
pubmed: 29728293
Int J Ment Health Syst. 2018 Jul 31;12:43
pubmed: 30079100
Lancet Psychiatry. 2020 Jun;7(6):463
pubmed: 32380007
PLoS Med. 2020 Sep 17;17(9):e1003306
pubmed: 32941435
Brain Behav Immun. 2020 Jul;87:100-106
pubmed: 32353518
World Psychiatry. 2016 Jun;15(2):166-74
pubmed: 27265707
JAMA Netw Open. 2020 Sep 1;3(9):e2023282
pubmed: 32997123
Psychiatry Res. 2020 Jun;288:112980
pubmed: 32315881